RESEARCH ARTICLE

Doliroside A from *Dolichos falcata* Klein suppressing amyloid β -protein 42 fibrillogenesis: An insight at molecular level

Dongpu Li¹✉, Hongfei Yu²✉, Qinxiong Lin³✉, Yun Liu²*✉

1 Tianjin Medical University General Hospital, Tianjin, China, **2** Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China, **3** Pharmaceutical College, South-Central University for Nationalities, Wuhan, China

✉ These authors contributed equally to this work.

* liuyun@mail.buct.edu.cn, liuyunprivate@sina.com

Abstract

A bioactive chemical constituent, doliroside A, from Chinese traditional herbal medicine *Dolichos falcata* Klein was isolated, purified and identified by 60% ethanol extraction, thin layer chromatography (TLC), high performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy. Molecular interaction mechanism between doliroside and amyloid β 42 protein was evaluated by thioflavin T fluorescence (ThT), circular dichroism (CD), atomic force microscope (AFM), and differential scanning calorimeter (DSC) from the aspects of kinetics, secondary structure, morphology, and thermodynamics, respectively. Results show that the purity of doliroside A is 99.9% by HPLC, and its chemical structure is identified by ¹H- and ¹³C-NMR. Doliroside A is observed to be concentration-dependent inhibiting the fibrillation of A β 42 with the IC₅₀ value of 26.57 $\pm$ 1.6 μ M. CD and DSC results imply that doliroside A can bind to the nuclei and oligomers of A β 42 to form a stable complex and suppress A β 42 fibrillation. AFM images show that doliroside A, after bound to the nuclei and oligomers, redirect A β 42 into off-pathway, amorphous oligomers. These findings not only provide a full insight into the molecular interaction mechanisms between A β 42 and doliroside A, but also facilitate the development of new native anti-AD drug of doliroside A compound.

OPEN ACCESS

Citation: Li D, Yu H, Lin Q, Liu Y (2017) Doliroside A from *Dolichos falcata* Klein suppressing amyloid β -protein 42 fibrillogenesis: An insight at molecular level. PLoS ONE 12(10): e0186590. <https://doi.org/10.1371/journal.pone.0186590>

Editor: Eugene A. Permyakov, Russian Academy of Medical Sciences, RUSSIAN FEDERATION

Received: June 13, 2017

Accepted: September 27, 2017

Published: October 30, 2017

Copyright: © 2017 Li et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was funded by the Ministry of Finance and the Ministry of Education of China. Additionally, this work was funded by the Beijing Municipal Natural Science Foundation (5142013 to YL) and the Fundamental Research Funds for the Central Universities, South-Central University for Nationalities of China (CZY10014 to QL). DSC equipments were provided by Prof. Zhaofeng Jiang and Dr. Ping Chang in Beijing Union University. The

Introduction

Alzheimer's disease (AD) is the most common neurodegenerative disease with the characterization of progressive loss of memory, aphasia and agnosia [1] especially popular in developed countries [2]. One of the main causes of AD is the aggregation of amyloid β -protein (A β) from soluble random-coil into β -sheet-rich fibrils [3]. Rajasekhar et al. [4] reviewed the A β aggregation mechanism and its toxic effects, and summarized the different classes of molecules to inhibit amyloidogenic precursor protein processing, A β oligomerization or fibrillogenesis. On the basis of the numbers of amino acids in the backbone structure, A β protein contains several different species (A β 39–43). Among them, amyloid β -protein 42 (A β 42) fibrillogenesis has

fundings had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: A β 42, Amyloid β -protein 42; AD, Alzheimer's disease; AFM, Atomic force microscope; CD, Circular dichroism; DA, Doliroside A; DSC, Differential scanning calorimeter; HPLC, High performance liquid chromatography; NMR, Nuclear magnetic resonance; PBS, Phosphate buffer solution; ThT, Thioflavin T; TLC, Thin layer chromatography; Tm, Thermodynamic parameter.

been widely considered as the most crucial key for the onset of AD due to its extremely severe neurotoxicity [5–7]. A common therapeutic strategy against AD pathology is to prevent A β 42 fibrillation [7]. Numerous studies have demonstrated that native small molecular compounds, such as (–)-epigallocatechin-3-gallate (EGCG) [8] [9], myricetin [10], resveratrol [11], and tramiprosate [12] (Gervais et al., 2007), can suppress A β 42 fibrillogenesis, which will form low toxicity aggregate structure.

Therefore, it is very urgent and important to search for more and more native active inhibitors against A β 42 fibrillogenesis to prevent AD pathology. Recently, increasing interests have been focused on Chinese traditional herbal drugs and their active ingredients against AD pathology treatment in China. However, the molecular interaction mechanisms of A β 42 and those bioactive chemical constituents from herbal drugs remain unclear to date.

Dolichos falcata Klein, a Chinese Dai ethnic medicine popularly known as “Tuoyeteng” in Yunnan province of China, has been widely used as a traditional herbal medicine to treat the fracture and beriberoid disease throughout the country, especially in countryside of China [13]. The voucher specimen of *Dolichos falcatus* Klein (No. 0610449, listed in Figure A in [S1 File](#)) has been kept in the Chinese Academy of Sciences Kunming Institute of Botany (Kunming, China). Since 2010, this plant is also called as *Dolichos tenuicaulis* (Baker) Craib, which is found in the Flora of China. It has been reported that *Dolichos falcata* Klein is popularly employed in medicinal preparations in China, such as “Yunnan Hongyao Jiaonang” in the market and “Damayao San” in clinical application, to treat fracture, rheumatoid arthritis, and soft tissue injuries by dispelling wind-evil and eliminating dampness, and activating blood flow and removing blood stasis according to the theory of Chinese medicine [13].

Previous phytochemical studies have demonstrated that there are several biological active substances in the root and leaves of *Dolichos falcata* Klein, such as saponins, flavonoids, and triterpenes compounds, among which doliroside A is one of the major triterpene components to contribute to the anti-gouty arthritis effect [13] [14]. The content of doliroside A, a well-known active compound, in *Dolichos falcata* Klein plant was approximate 4% based on dried plant powder in the literature. However, in our present work, the HPLC fingerprints are reported on the methanol extracts of *Dolichos falcata* Klein plant (seen in [Fig 1](#)). From HPLC curves, it is clearly obtained that the active compound, doliroside A (its retention time is 19.347 min in our work), is isolated and identified in our present work. The content of doliroside A is estimated to be 5.62%–7.5% based on dried plant powder dependence on the place of plant origin production. For instance, the content of doliroside A in this plant originating from Dali county in Yunnan province is about 5.62% based on dried plant powder, while the content doliroside A originating from Binchuan county in Yunnan province is about 7.5% based on dried plant powder.

Dolichos falcata Klein plant as a traditional medicine is popular among the people in rural areas in China, such as inflammation, diuresis, and wound healing [13] [15–18]. Using traditional Chinese herbs to cure diseases in clinics have been acknowledged by people throughout the world, especially in China. And a lot of such articles have been available in the literature. For instance, Gao et al. [19] reviewed research progress on natural products from traditional Chinese medicine in treatment of Alzheimer's disease in 2013. Ruszkowski et al. [20] demonstrated that triterpenoids from traditional Chinese herbs could treat or slow the progression of neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's Disease (AD), Huntington's disease. Liu et al. [21] reported that Xanthoceraside, a triterpenoid saponin extracted from *Xanthoceras sorbifolia* Bunge, showed positive effects in several Alzheimer's disease. Du et al. [22] studied the molecular 108 mechanism underlying anti-inflammatory action of the triterpenoid saponin, Xanthoceraside. However, to date, no information has been available on the doliroside A for the treatment of AD pathology in the literature. In this case, the present

TLC separation

HPLC

Fig 1. Two compounds, (1) medicagenicacid-3-O- β -D-glucopyranoside (MG), and (2) doliroside A (DA), separated by TLC (left up) and HPLC (left down) chromatography. The structure of doliroside A was identified by NMR (right).

<https://doi.org/10.1371/journal.pone.0186590.g001>

study aims to extract and purify doliroside A from *Dolichos falcata* Klein, and assess the anti-AD pathology activities of this active compound from the molecular interaction mechanisms between doliroside A and A β 42.

To meet above-mentioned challenge, doliroside A was firstly isolated, purified and identified using classical methods of methanol extraction, thin layer chromatography (TLC), high performance liquid chromatography (HPLC) and nuclear magnetic resonance (^1H - and ^{13}C -NMR) spectroscopies. Subsequently, the activities of doliroside A on anti-aggregating A β 42 was evaluated to elucidate the molecular interactions between doliroside A and A β 42 through thioflavin T (ThT) fluorescence spectroscopy, circular dichroism (CD) spectroscopy, atomic force microscope (AFM), and differential scanning calorimeter (DSC). The final results may support the wide utility as well as exploit a new clinical application in AD pathology of *Dolichos falcata* Klein in Chinese Dai ethnic medicine.

Materials and methods

Materials

The plant roots of *Dolichos falcata* Klein were bought from medicinal market in Yunnan province, China. The herbs were identified by Prof. Dingrong Wang, College of Pharmaceutical Sciences, South-Central University for Nationalities, China. A β 42 peptide was purchased from GL Biochem (Shanghai) Ltd. (Shanghai, China) with the purity of higher than 95%. The amino acid sequence of A β 42 is DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA. A β 42 was kept in -80°C fridge. Hexafluoroisopropanol (HFIP) with the purity of more than 99.5% was purchased from Sigma (St. Louis, MO, USA). Methanol (HPLC gradient grade) and butanol (AR grade) were purchase from China National Pharmaceutical Group Co. (Beijing, China). Other chemicals and agents were all of the analytic grades and bought from local markets in Beijing, China.

Extraction, purification and identification of doliroside A from *Dolichos falcata* Klein

0.5 kg of the dried and powdered (sieved by 40 meshes) plant root was extracted with 60% methanol (solid/liquid ratio, 1:10 w/v) at 80°C for 2-h refluxing. Methanol crude extract (50 g) was extracted with butanol and then subjected to repeated chromatography on GF254 silica gel column and eluted with petroleum ether-ethyl acetate (50:1–1:1) and ethyl acetate-methanol (30:1–10:1) gradient solvent system. Two purified compounds, medicagenicacid-3-O- β -D-glucopyranoside and doliroside A, were obtained through recrystallization with methanol and acetone. The extraction flow chart of medicagenicacid-3-O- β -D-glucopyranoside and doliroside A was shown in Figure B in [S1 File](#). The purification of this resulting compound was performed by HPLC methods. HPLC conditions: UltiMate 3000 High performance liquid chromatograph (HPLC); Nucleosil C18 (4.6mm $\times$ 250mm $\times$ 5 μm) is used as chromatographic column; column temperature is 30°C ; detection wavelength is 212 nm; Mobile phase is the mixture acetonitrile/ 0.1% acetic acid with the flow rate of 0.5mL/min. Finally, 200 mg white crystal compound was obtained, and its chemical structure was confirmed by ^1H - and ^{13}C -NMR spectroscopies. NMR conditions: Bruker Avance II 400MHz nuclear magnetic resonance spectrometer; CD $_3$ OD is used as solvent.

Content analysis of doliroside A by highperformance liquid chromatography (HPLC)

The purification of the isolated compound was performed on an UltiMate 3000 HPLC system (Shanghai, China). The content was analyzed using a Venusil MP C18 column (4.6 mm id $\times$ 250 mm, 5 μm) with the UV detector wavelength at 212 nm. Column temperature was 30°C . The mobile phase used in separation included acetonitrile (solvent A) and 1% acetic acid (v/v) (solvent B). A gradient program was used as follows: 0–15 min, 10–50% A; 15–25 min, 50–35% A; 25–35 min, 35–100% A; 35–45 min, 100–10% A. The flow rate of mobile phase was set at 0.3 ml/min.

Structural characterization of doliroside A by ^1H - and ^{13}C -NMR measurement

Doliroside A structure was characterized by a Bruker Avance 500 Hz NMR spectrometer (Bruker, Germany) equipped with a 5-mm inverse-configuration probe with triple-axis-gradient capability at a field strength of 14.1T operating at 500.1, and 150.9MHz for ^1H and ^{13}C nuclei, respectively, at 303K with sample contained in CD $_3$ OD [23]. The chemical shifts of ^1H and ^{13}C

nuclei are reported relative to [tetramethylsilane](#) (TMS) ($\delta = 0$ ppm for both ^1H and ^{13}C) using the solvent signals as secondary internal reference.

r parameter determination

To facilitate the comparison of experimental data under various tested conditions, *r* representing the molar concentration ratio of doliroside A to A β 42 was introduced in this work. It was calculated as follows:

$$r = \frac{[\text{doliroside A}]}{[\text{A}\beta 42]}$$

where [doliroside A] and [A β 42] are the final molar concentrations of doliroside A and A β 42 ($\mu\text{mol/L}$) in phosphate buffer solution (PBS) (100 mM, pH 7.4), respectively.

The final molar concentration of A β 42 in PBS was 25 $\mu\text{mol/L}$, and the final molar concentrations of doliroside A in PBS were 2.5, 12.5, 25, 125, and 250 $\mu\text{mol/L}$, respectively. Therefore, in this work, the values of *r* were calculated at 0.1, 0.5, 1, 5, and 10, respectively.

Fibrillation kinetics monitored by Thioflavin T (ThT) fluorescence spectroscopy

ThT fluorescence spectroscopy was employed to monitor the fibrillation kinetics of A β 42 (25 μM in PBS, pH 7.4) in the absence and presence of dolisoride A at different concentrations (2.5 μM , 12.5 μM , 25 μM , 125 μM , and 250 μM in PBS, pH 7.4) at 37°C with the agitation of 200 rpm [24]. At appropriate intervals, aliquot of 200 μL samples was removed from the bulk solution and mixed with 2 mL of 20 μM ThT in PBS (pH 7.4). The solution was injected into a 1 cm-path length quartz cuvette and characterized by a Varian Cary Eclipse fluorescence spectrometer (California, USA). The excitation wavelength was 440 nm, and emission wavelength was 480 nm [21]. The excitation and emission slits were both 10 nm. The scanning rate was 100 nm/min and the resolution was 1.0 nm.

Thermodynamic parameter assessment by differential scanning calorimetry (DSC)

DSC curve was employed to investigate the transition midpoint temperature (T_m) of A β 42 in the absence and presence of dolisoride A at different concentrations (25 μM , 125 μM , and 250 μM) during the fibrillation process. DSC measurement was performed on a Malvern MicroCal VP-DSC (MicroCal, Northampton, MA). The sample cell was loaded with the A β 42 solution (25 μM in PBS, pH 7.4), and the same concentration PBS was loaded into the reference cell as the blank control. Noticeably, the samples and control were degassed for 15 min immediately before DSC scanning. A buffer-buffer reference scan was subtracted from each sample scan prior to concentration normalization. Analysis conditions were: starting temperature 25°C, final temperature 90°C, scan rate 1.5°C/min, prescan 5 min, postscan 0 min, filtering period 10 s. DSC data were analyzed by MicroCal Origin Version 7.0.

Conformation analysis by far-UV circular dichroism (CD) spectroscopy

The A β 42 protein conformation variances were carried out in a JASCO J-810 automatic recording spectropolarimeter (Jasco Inc., Tokyo, Japan) controlled by the Jasco software. Briefly, A β 42 (25 μM) in the absence and presence of doliroside A (125 μM) were incubated at 37°C for assigned periods. After co-incubation, the samples were centrifuged at 5,000 rpm for 15 min, and the supernatant was injected into a 1-mm path length quartz cuvette. A

background CD spectrum of buffer solution was subtracted from the sample spectrum for baseline correction. Spectra were recorded under the conditions: a resolution of 0.5 nm, scanning rate of 100 nm/min, response time of 1 s, bandwidth of 2 nm, room temperature and the wavelength ranges from 250 to 190 nm. Morphology detection by atomic force microscope (AFM).

10 μ L samples were pipetted onto freshly cleaved mica plate (1 cm $\times$ 1 cm) fixed onto a glass slide and incubated at room temperature for 3 min. The remaining salts and loose deposits in the suspension were triplicate rinsed with ultrapure water (50 μ L, Millipore) and then air-dried for a whole night (12 h). AFM images were obtained on a dimension FastScan AFM (Bruker, German) with FASTSCAN-A probe in ScanAsyst mode under ambient conditions. Scanning frequency was 1.95 Hz.

Data statistical analyses

All values were expressed as the mean $\pm$ SD, and were analyzed by the Origin Pro 8.0 software (Origin Lab, USA).

Results and discussion

Structure identification of doliroside A from *Dolichos falcata* Klein

From the HPLC fingerprinting curves of methanol extracts from *Dolichos falcata* Klein, two components, medicagenic acid-3-O- β -D-glucopyranoside (MG, yield 0.5 g) and doliroside A (DA, yield 1.5 g), were isolated and purified from methanol extract by TLC and HPLC (Fig 1). The purities of two compounds were all tested to be higher than 99.5% by HPLC analysis. The chemical structures of the two purified compounds, DA and MG, are confirmed and identified by ^1H - and ^{13}C -NMR. The NMR images of DA are shown in Fig 1, and the NMR curves of MG are depicted in Figure C in S1 File.

As shown in Fig 1, the chemical shifts of ^1H and ^{13}C nuclei are reported relative to TMS ($\delta = 0$ ppm for both ^1H and ^{13}C) using the solvent signals as secondary internal references. The ^1H -NMR (CD_3OD , 500 MHz) spectrum of doliroside A revealed six methyl groups information (δ H 0.92, 0.97, 1.03, 1.28, 1.52, 1.97), and ^{13}C -NMR (CD_3OD , 500 MHz) showed the C chemical shifts δ . 43.49 (C-1), 68.76 (C-2), 83.33 (C-3), 51.04 (C-4), 51.10 (C-5), 19.9 (C-6), 32.06 (C-7), 40.00 (C-8), 47.49 (C-9), 35.76 (C-10), 22.59 (C-11), 121.46 (C-12), 143.79 (C-13), 40.80 (C-14), 27.06 (C-15), 21.44 (C-16), 45.70 (C-17), 41.42 (C-18), 45.40 (C-19), 30.33 (C-20), 33.30 (C-21), 32.78 (C-22), 178.56 (C-23), 13.35 (C-24), 16.04 (C-25), 16.72 (C-26), 25.57 (C-27), 199.75 (C-28), 32.14 (C-29), 23.07 (C-30), 73.68 (C-2'), 76.76 (C-3'), 70.05 (C-4'), 76.46 (C-5'), 61.02 (C-6').

From NMR data, the chemical structure of doliroside A, a major triterpenoid compound in *Dolichos falcata* Klein, was elucidated and shown in Fig 2. Chen and co-workers [13] demonstrated that doliroside A showed a significant effect on improving symptoms of acute gouty arthritis induced by monosodium urate crystals through inhibiting the production of pro-inflammatory cytokines. Wei and co-workers [14] reported that doliroside A attenuated monosodium urate crystals-induced inflammation by targeting nucleotide-binding domain and leucine-rich repeat containing protein 3 (NLRP3) inflammasome. It seems that doliroside A is an active compound against inflammation in jures [13][15–18]. However, no information has been available on the doliroside A for the treatment of AD pathology in the literature. In this case, the present work investigated the molecular interaction mechanism between A β 42 and doliroside A to assess the anti-AD pathology activities of this active compound for the first time.

Fig 2. Chemical structural formula of doliroside A isolated from *Dolichos falcata* Klein.

<https://doi.org/10.1371/journal.pone.0186590.g002>

Effect of doliroside A on the fibrillation kinetics of A β 42

It has been reported that A β protofibrils and fibrils are rich in parallel β -sheets. ThT can be used as a probe for the assay of parallel β -sheet structure [25] (Blanchard et al., 2004), and the ThT fluorescence intensity at 480 nm (I480) is linearly related to the mass of A β 42 fibrils [26]. Hence, the A β 42 fibrillation kinetics in absence and presence of doliroside A could be quantified by I480 [27]. The results are shown in Fig 3.

As shown in Fig 3, the fibrillation of A β 42 alone displayed a typical sigmoidal curve at the physiological condition (37°C and 100 mM PBS), and it contained three main stages of the fibrillation process: the lag phase of 0–5 h (1st phase) where I480 showed slight changes, the exponential growth phase of 5–24 h (2nd phase) where I480 increased exponentially with time, and the stable phase of > 24 h (3rd phase) where I480 reached a plateau indicating the end of fibrillation process. The A β 42 fibrillation process is a nucleation-dependent process, which sequentially contains three characteristic stages on a macroscopic level to form nanoscale amyloid fibrils [4] [28]: The 1st phase is an initial slow nucleation stage, during which natively unfolded A β 42 molecules form β -sheet-rich structure, assembling into initial nuclei. During the 2nd phase, monomers and higher order oligomers elongate the nuclei into protofibrils. At the 3rd phase, protofibrils further elongate into mature fibrils, leading to the end of the fibrillation.

Fig 3 also showed that doliroside A concentration-dependently inhibited the fibrillation of A β 42. In other words, the ThT fluorescence intensity decreased with the increase of doliroside A concentrations from 2.5 to 250 μ mol/L ($r = 0.1$ –10). From these data, the 50% inhibition

Fig 3. Kinetics of A β 42 fibrillation in the absence and presence of doliroside A. The concentrations of A β 42 and doliroside A were 25 μ M and 2.5–250 μ M, respectively. The r values derived from Eq. (1) were in the range of 0.1 to 10. Experiments were carried out in 100 mM PBS (pH7.4) at 37°C.

<https://doi.org/10.1371/journal.pone.0186590.g003>

concentration (IC_{50}) for doliroside A was calculated to be 26.57 ± 1.6 μ M. When r value was increased from 0.1 to 5, I480 declined significantly, while the further increase of r value from 5 to 10 just caused slight decrease of I480.

Effect of doliroside A on the secondary structure of A β 42

The fibrillation of A β 42 involves the conversion of unfolded A β 42 molecules into β -sheet structure, the formation of highly ordered and β -sheet-rich nuclei, the elongation of nuclei to protofibrils, and the formation of insoluble β -sheet-rich mature fibrils [29]. Consequently, the change of β -sheet contents is a typical characteristic of the A β 42 fibrillation [4]. So we further evaluated the effect of doliroside A on the secondary structure changes of A β 42 during its fibrillation by CD spectroscopy. The CD spectra of A β 42 without and with doliroside A were shown in the embedded graphs of Fig 4A and 4B.

As can be seen in the upper right corner of Fig 4A, the fibrillation of A β 42 alone was accompanied by the conversion of secondary structure from random coil (characterized by the minimum at 200 nm) to β -sheet (characterized by the minimum at 216 nm). Since the β -sheet content is positively related to the intensity of CD at 216 nm ($-Mdeg_{216nm}$), the negative $Mdeg_{216nm}$ was plotted as a function of incubation time to visually see the changes of β -sheet contents during the A β 42 fibrillation (Fig 4A). Prior to 15 h, the β -sheet contents increased with the increase of incubation time, which agreed well with the results in Fig 3 that unordered A β 42 molecules gradually converted into β -sheet structure, nucleating, and elongating into protofibrils during 0 to 15 h. After 15 h, the β -sheet contents unexpectedly decreased and then plateaued at about 25 h. 15–25 h, as shown in Fig 3, was the second half of the exponential growth phase (the 2nd phase), at which protofibrils assembled into insoluble mature fibrils. So the fall of β -sheet content within this period mainly stemmed from the precipitation of

Fig 4. The intensity of CD at 216 nm ($-Mdeg_{216nm}$) of A β_{42} (25 μ M) with the absence (A) and presence (B) of doliroside A (125 μ M). The embedded graphs were the corresponding CD spectra at different incubation times.

<https://doi.org/10.1371/journal.pone.0186590.g004>

insoluble fibrils during centrifugation before the CD assay (see the [method](#) section for detail information) [21]. This result was in consistence with that observed by Ruggeri et al. [30] during the study of influence of β -sheet content on the mechanical properties of A β_{42} fibrils. The decrease of β -sheet content was ascribed to the sedimentation of insoluble aggregates during the measurement [30].

When doliroside A was added into the A β_{42} solution in the initial lag phase, the negative $Mdeg_{216nm}$ firstly increased rapidly at 0–5 h (the lag phase), and then slowly increased at 5–15 h. After 15 h, the $Mdeg_{216nm}$ remained almost constant. It indicates that the β -sheet content became unchanged at this time (Fig 4B). It can be observed that the $-Mdeg_{216nm}$ maximum of A β_{42} in the presence of doliroside A (6.10 ± 0.03) was lower than that of A β_{42} alone (6.79 ± 0.13), indicating that doliroside A prevented the increase of β -sheet content to some extent. Moreover, in the presence of doliroside A, the β -sheet content did not show decrease after 15 h, which suggested that doliroside A inhibited the formation of insoluble β -sheet-rich fibrils. Based on our experimental data, compound doliroside A inhibit A β fibril formation but do not inhibit oligomer formation. The results revealed that doliroside A compound appears to inhibit Abeta fibrillization by binding and stabilizing early oligomeric species, thus inhibiting the formation of larger aggregates. However, many studies have shown that early oligomeric species rich in beta-sheet could be even more toxic than fibrils to cells [4] [31] [32]. This cytotoxicity assay of A β oligomeric species is ongoing in our lab and will published in another paper in future.

Effect of doliroside A on morphology of A β_{42} aggregates

The morphology of A β_{42} aggregates in the absence and presence of doliroside A was detected by AFM after 24-h incubation, and the AFM images were shown in Fig 5. Compared with the AFM image of A β_{42} alone in Fig 5A, amorphous aggregates, instead of fibrils, appeared at the equilibrium stage when adding doliroside A, revealing that the active compound doliroside A could suppress A β_{42} fibrillation and redirect it into off-pathway amorphous aggregates.

Effect of doliroside A on the thermodynamic parameter (T_m) of A β_{42}

To address the effects of doliroside A on the thermostability of A β_{42} at different fibrillation phases, the DSC curves of A β_{42} were evaluated at different r values when doliroside A were added in the initial lag phase (0–10 h), growth phase (10–18 h), and stable phase (20–30h). The DSC curves were shown in Fig 6 and the transition midpoint temperature (T_m) values picked from the DSC curves were listed in Table 1.

It was obviously observed from Fig 6A that there existed different T_m values at the three stages of A β_{42} fibrillation process. At 0–10 h, the 1st phase, T_{m1} value decreased with the incubation time from 53.7 to 50.17°C, indicating that the thermostability of A β_{42} declined. Within this period, A β_{42} formed nuclei and oligomers according to the Th T intensity (Fig 3). The T_{m1} value decrease was probably ascribed to the fact that some early species of abeta gradually lost their stability as the aggregation process moved on. At 12–18 h, the 2nd phase, another transition midpoint temperature, T_{m2} , appeared and remained a constant value of 70°C within this stage. It suggested that more stable species were formed in the solution. At the fast growth phase, A β_{42} alone showed broad peak width and two T_m values (Fig 6C, black line), indicating that oligomers and protofibrils co-existed. At 20–30 h, the 3rd phase, T_{m1} and T_{m2} merged into

Fig 5. The morphology of A β 42 aggregates in absence (A) and presence (B) of doliroside A added at stable phase (24 h) (the content of doliroside is 125 mM, $r = 5$).

<https://doi.org/10.1371/journal.pone.0186590.g005>

T_{m3} and gradually increased from 60 to 67°C. The combination of T_{m1} and T_{m2} indicated that most of the nuclei, oligomers, and protofibrils have formed relatively homogeneous mature fibrils at this stage. Moreover, the increase of T_{m3} value at 20–24 h was assigned to the secondary fibrillation and the formation of more stable and wider branched fibrils described in AFM images (Fig 5A).

By adding different concentrations of doliroside A into A β 42 solution in the three steps of A β 42 fibrillation process at 3 h, 12 h and 24 h, respectively, the impacts of doliroside A on the thermostability of A β 42 were examined. From Fig 6B and Table 1, it can be found that, in the 1st phase, T_{m1} value slightly increased from 53 to 57°C when adding doliroside A at $r = 1$. In cases of $r = 5$ and 10, another transition midpoint temperature (T_{m2}) appeared, indicating that

Fig 6. Effects of doliroside A concentration on thermodynamic parameter (T_m) of A β 42 for three steps of the A β 42 fibrillation process when added at 3 h, 12 h and 24 h, respectively. A β 42 concentration was 25 μ M and doliroside A concentration could be calculated from the r values shown in the figure.

<https://doi.org/10.1371/journal.pone.0186590.g006>

Table 1. The transition midpoint temperature (T_m) calculated from DSC curves of A β 42 in absence and presence of doliroside A.

$r = [\text{doliroside A}]/[\text{A}\beta 42]$	Lag phase (1 st phase)		Growth phase (2 nd phase)		Stable phase (3 rd phase)
	T_{m1} ($^{\circ}\text{C}$)	T_{m2} ($^{\circ}\text{C}$)	T_{m1} ($^{\circ}\text{C}$)	T_{m2} ($^{\circ}\text{C}$)	T_{m3} ($^{\circ}\text{C}$)
0	53.7 $\pm$ 0.06	/	50.17 $\pm$ 0.16	71.75 $\pm$ 0.22	67.47 $\pm$ 0.08
1	57.11 $\pm$ 0.13	/	54.86 $\pm$ 0.86	67.85 $\pm$ 0.45	67.57 $\pm$ 0.11
5	62.41 $\pm$ 0.77	71.92 $\pm$ 0.47	66.48 $\pm$ 0.95	/	65.96 $\pm$ 1.20
10	61.79 $\pm$ 1.50	72.84 $\pm$ 0.79	66.44 $\pm$ 0.10	/	66.87 $\pm$ 1.30

<https://doi.org/10.1371/journal.pone.0186590.t001>

doliroside A stimulated A β 42 molecules to form more stable complexes at the lag phase. Namely, doliroside A could redirect the fibrillation pathway of A β 42 from the lag phase. When doliroside A was added at 2nd phase of A β 42 fibrillation, the T_{m1} and T_{m2} values merged and the peak width became narrower (Fig 6C) with increasing r values, suggesting that the homogeneity was increased by doliroside A. For instance, at $r = 5$ and 10, both T_{m1} and T_{m2} values disappeared and the T_{m3} value appeared which remained at 66.4 $^{\circ}\text{C}$. When doliroside A was added at the last phase, the T_{m3} value remained almost constant, the curves became shaper and narrower ($r \geq 5$), the T_m values were slightly lower than A β 42 alone (seen in Fig 6A and Table 1).

Interactions mechanism between doliroside A and A β 42 protein

In this work, we for the first time reported that doliroside A extracted from *Dolichos falcata* Klein could concentration-dependently suppress the fibrillation of A β 42 with the IC_{50} value of $26.57 \pm 1.6 \mu\text{M}$. Similar inhibitory behaviors were found with other native small molecules. For instance, Viet and co-workers [33] reported that dihydrochalcone from Eastern herbs and plants reduced the ThT fluorescence intensity of A β 42 fibrils in a concentration-dependent manner (from 1 to 100 mM). The concentration of A β 42 they used were 25 μM , which was the same as that in this study. In the presence of 1 mM Dihydrochalcone, the exponential growth phase was significantly decreased. Upon the addition of 100 mM dihydrochalcone, the I480 was decreased to ca. 66%. Shimmyo and co-workers [10] believed that myricetin could inhibit A β 42 aggregation in a dose-dependent manner. When the myricetin concentration was 0.1 μM , weak inhibition activity was observed. In cases of myricetin concentration of 1 μM and 10 μM , the inhibitory rate of myricetin on A β 42 aggregation was enhanced from almost zero to $65.2 \pm 5.1\%$ [10].

The results in Fig 3 showed that doliroside A almost had no impact on the lag phase of A β 42, while the T_m value in Fig 6B and Table 1 indicated that doliroside A could bind to A β 42 and form more stable species when added in the lag phase. These phenomena implied that doliroside A mainly bound to the nuclei and oligomers of A β 42 rather than monomers, which could not prolong the lag phase, but could significantly suppress the fast growth phase (Fig 3) [10] [23]. This deduction could also be supported by the CD result in Fig 4, which showed that the within the lag phase (0–5 h), the β -sheet content rapidly increased, while in the growth phase (5–24 h), the β -sheet content increased very slowly.

In our previously study, we investigated the interactions between A β 42 protein and (–)-epigallocatechin 3-gallate (EGCG), the main component of green tea [21]. Although both doliroside A and EGCG redirected A β 42 into off-pathway, amorphous aggregates (seen in Fig 5B), the interaction mechanisms were distinct. EGCG mainly bound to the unfolded A β 42 molecules and prolonged the lag phase of A β 42 fibrillation [21], while doliroside A bound to the nuclei and oligomers to form more stable complexes and slowed down the growth phase of A β 42.

Conclusions

In order to support the wide utility as well as exploit a new clinical application in AD pathology of *Dolichos falcata* Klein in Chinese Dai ethnic medicine, a triterpenoid active compound, doliroside A from this Chinese traditional herb was isolated, purified and identified by classic approaches, such as 60% methanol extraction, TLC, HPLC and NMR. The molecular interaction mechanisms between doliroside A and A β 42 were elucidated for the first time via Th T fluorescence and CD spectroscopies, AFM, and DSC analyses. In conclusion, doliroside A showed the ability of suppressing A β 42 aggregation in a concentration-dependent way with the IC_{50} value of 26.57 ± 1.6 μ M. The inhibitory mechanisms of A β 42 fibrillation was attributed to the fact that doliroside A could bound to the nuclei and ordered oligomers of A β 42 to form more stable complexes, reducing the β -sheet content and redirecting it into off-pathway, amorphous aggregates. It is undoubted to speculate that doliroside A is a native promising inhibitor candidate against A β 42 fibrillogenesis, which is helpful to take precaution against amyloid neurodegenerative diseases in future.

Supporting information

S1 File. Figure A.) The voucher specimen of *Dolichos falcatus* Klein (No. 0610449) in the Chinese Academy of Sciences Kunming Institute of Botany, Yunnan, China. **Figure B.)** The extraction flow chart of medicagenicacid-3-O- β -D-glucopyranoside and doliroside A from *Dolichos falcata* Klein. **Figure C.)** NMR analysis of medicagenicacid-3-O- β -D-glucopyranoside. NMR conditions: Bruker Avance II 400MHz nuclear magnetic resonance spectrometer (CD3OD is used as Solvent). (DOC)

Acknowledgments

The authors also acknowledge the long-term subsidy mechanism from the Ministry of Finance and the Ministry of Education of China for supporting AFM experiments. Additionally, this work was funded by the Beijing Municipal Natural Science Foundation (5142013) and the Fundamental Research Funds for the Central Universities, South-Central University for Nationalities of China (CZY10014). DSC equipments were provided by Prof. Zhaofeng Jiang and Dr. Ping Chang in Beijing Union University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

Author Contributions

Conceptualization: Yun Liu.

Funding acquisition: Yun Liu.

Investigation: Hongfei Yu, Qinxiong Lin.

Supervision: Yun Liu.

Writing – original draft: Dongpu Li.

Writing – review & editing: Yun Liu.

References

1. Gunther EC, Strittmatter SM. β -amyloid oligomers and cellular prion protein in Alzheimer's disease. J. Mol. Med. 201; 88: 331–338.

2. Churches QI, Caine J, Cavanagh K, Epa VC, Waddington L, Tranberg CE, et al. Naturally occurring polyphenolic inhibitors of amyloid beta aggregation Bioor. Med. Chem. Lett. 2014; 24: 3108–3112.
3. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006; 314:777–781.
4. Rajasekhar K, Madhu C, Govindaraju T. Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity. ACS Chem. Neurosci., 2016; 7: 1300–1310. <https://doi.org/10.1021/acschemneuro.6b00175> PMID: 27355515
5. Joshi P, Turola E, Ruiz A, Bergami A, Libera DD, Benussi L, et al. Microglia convert aggregated amyloid- β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014; 21:582–593.
6. Kam TI, Gwon Y, Jung YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease Cell. Mol. Life Sci. 2014; 71:4803–4813.
7. Xu J, Zeng C, Cruchaga C, Goate A, Mach RH. Alzheimer's therapeutics targeting amyloid beta 1–42 oligomers II: Sigma-2/PGRC1 receptors mediate A β 42 oligomer binding and synaptotoxicity. Plos One. 2014; 9:e111899. <https://doi.org/10.1371/journal.pone.0111899> PMID: 25390692
8. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, et al. EGCG remodels mature α -synuclein and amyloid- β fibrils and reduces cellular toxicity Proc. Natl. Acad. Sci. USA. 2010; 107:7710–7715.
9. Wang SH, Liu FF, Dong XY, Sun Y. Thermodynamic analysis of the molecular interactions between amyloid β -peptide 42 and (–)-epigallocatechin-3-gallate. J. Phys. Chem. 2010; 114: 11576–11583.
10. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Multifunction of myricetin on A beta: neuroprotection via a conformational change of A beta and reduction of A beta via the interference of secretases. J. Neurosci. Res. 2008; 86:368–377
11. Ge JF, Qiao JP, Qi CC, Wang CW, Zhou J. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem. Int. 2012; 61:1192–1201. <https://doi.org/10.1016/j.neuint.2012.08.012> PMID: 22981725
12. Gervais F, Paquette J, Morissette C. Targeting soluble A β peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging. 2007; 28: 537–547.
13. Chen L, Mola M, Deng X, Mei Z, Huang X, Shu G, et al. Dolichos falcata Klein attenuated the inflammation induced by monosodium urate crystals in vivo and in vitro J. Ethnopharmacol. 2013; 150:545–552.
14. Wei H, Hu C, Xie J, Yang C, Zhao Y, Guo Y, et al. Dolioside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome. Eur. J. pharmacol. 2014; 740: 321–328.
15. Tian HY. Integration of Chinese Ethnic Drug Processing, China Ancient Books Publishing House Beijing, China. 2009; p.41.
16. Lin YF, Yi Z, Zhao YH. Chinese Dai Medicine Colorful Illustrations. Yunnan National Publishing House, Kunming, China 2003; 6:126.
17. State Administration of Traditional Chinese Medicine, Chinese Materia Medica-Volume of Dai Ethnic Drug Shanghai Scientific and Technical. Publishers, Shanghai, China. 2005; p.37.
18. Yu HC. Treatment of Chinese herbal medicine “DamayaoSan” on 86 cases of closed fracture and soft tissue injury. J. Chinese National Folk Med. 2000; 6:339–340.
19. Gao J, Inagaki Y, Liu Y. Research progress on flavonoids isolated from traditional Chinese medicine in treatment of Alzheimer's disease. Intractable Rare Dis Res., 2013, 7:3–10.
20. Ruszkowski P, Bobkiewicz-Kozłowska T. Natural triterpenoids and their derivatives with pharmacological activity against neurodegenerative disorders. Mini Reviews. Organic Chem. 2014; 11:307–315.
21. Liu Y, Liu Y, Wang S, Dong S, Chang P, Jiang Z. Structural characteristics of (–)-epigallocatechin-3-gallate inhibiting amyloid A β 42 aggregation and remodeling amyloid fibers. RSC Advances. 2015; 5: 62402–62413.
22. Du BS, Zhang ZY, Li N. Madecassoside prevents A β (25–35)-induced inflammatory responses and autophagy in neuronal cells through the class iii pi3k/beclin-1/bcl-2 pathway. Intern Immunopharm. 2014; 20: 221–228.
23. Khallouki F, Haubner R, Ricarte I, Erben G, Klika K, Ulrich CM, et al. Identification of polyphenolic compounds in the flesh of Argan (Morocco) fruits. Food Chem. 2015; 179:191–198.
24. Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, Liu X, et al. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. P. Natl. Acad. Sci. USA, 2008; 105: 6813–6818
25. Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigle P, Ingram VM. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule Proc. Natl. Acad. Sci. USA. 2004; 101:14326–14332.

26. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, et al. Proliferation of amyloid- β 42 aggregates occurs through a secondary nucleation mechanism. *Proc. Natl. Acad. Sci. USA*. 2013; 110:1–6.
27. LeVine H. Quantification of β -sheet amyloid fibril structures with thioflavin T Method. *Enzymol*. 1999; 309:274–284.
28. Arosio P, Knowles TP, Linse S. On the lag phase in amyloid fibril formation. *Phys. Chem. Chem. Phys.* 2015; 17: 7606–7618 <https://doi.org/10.1039/c4cp05563b> PMID: 25719972
29. Liang Y, Lynn DG, Berland KM. Direct observation of nucleation and growth in amyloid self-assembly. *J. Am. Chem. Soc.* 2010; 132: 6306–6308.
30. Ruggeri FS, Adamcik J, Jeong JS, Lashuel HA, Mezzenga R, Dietler G. Influence of the β -Sheet Content on the Mechanical Properties of Aggregates during Amyloid Fibrillization. *Angew. Chem. Int. Edit.* 2015; 54: 2462–2466.
31. Rajasekhar K, Chakrabarti M, Govindaraju T. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease, *Chem. Commun.* 2015; 51:13434–13450
32. Rajasekhar K, Suresh SN, Manjithaya R, Govindaraju T. Rationally Designed Peptidomimetic Modulators of Ab Toxicity in Alzheimer's Disease. *Sci. Rep.*, 2015; 5: 8139. <https://doi.org/10.1038/srep08139> PMID: 25633824
33. Viet MH, Chen CY, Chen YR, Li MS. Discovery of dihydrochalcone as potential lead for Alzheimer's disease: in silico and in vitro study. *Plos One*. 2013; 8: e79151. <https://doi.org/10.1371/journal.pone.0079151> PMID: 24260164